劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

已收盘 07-02 16:08:21

30.080

+0.640

+2.17%

最高34.000	最低29.700	成交量271.53万
今开31.800	昨收29.440	日振幅14.61%
总市值111.30亿	流通市值101.67亿	总股本3.70亿
成交额8,456万	换手率0.80%	流通股本3.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":30.08,"timestamp":1782979701008,"preClose":29.44,"halted":0,"volume":2715337,"delay":0,"changeRate":0.021739130434782507,"floatShares":338000000,"shares":370000000,"eps":-7.008391299573295,"marketStatus":"已收盘","change":0.64,"latestTime":"07-02 16:08:21","open":31.8,"high":34,"low":29.7,"amount":84561369,"amplitude":0.14606,"askPrice":30.24,"askSize":297600,"bidPrice":30.08,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-6.193247270331326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":5,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":29.44,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":1.414965,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"2648572826","title":"【券商聚焦】申万宏源首予劲方医药-B(02595)“买入”评级 指其RAS疗法具全球领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2648572826","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648572826?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:51","pubTimestamp":1782975101,"startTime":"0","endTime":"0","summary":"报告首次覆盖给予“买入”评级，目标价34.81港元。研报核心逻辑围绕公司核心管线GFH375的全球领先地位展开。GFH375是一款靶向KRAS G12D高频突变的口服抑制剂，该突变在胰腺癌中突变率约40%，且与不良预后密切相关。公司核心产品GFH375预计于2028年上市并开始贡献产品销售收入。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984986","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000166","09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647323800","title":"劲方医药-B午后涨超15% 交银国际维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647323800","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647323800?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:22","pubTimestamp":1782710520,"startTime":"0","endTime":"0","summary":"　　劲方医药-B午后股价上涨15.06%，现报27.96港元，成交额4010.55万港元。　　据劲方医药官微消息，公司宣布GFH375/VS-7375进入一项II期海外研究，治疗KRAS G12D突变型转移性胰腺导管腺癌，并已于近日完成首例患者入组。　　交银国际发布研报称，将劲方医药的投资评级及目标价，分别维持“买入”评级及目标价51港元。该行称，KRAS G12D 抑制剂海外临床及合作进展理想。交银国际认为,优异的海外初步数据对 VS7375 的同类最佳潜性提供进一步佐证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-29/doc-inifacku5422211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647285693","title":"劲方医药-B(02595.HK)：拟不超3.5亿港元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2647285693","media":"中金财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647285693?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:27","pubTimestamp":1782707222,"startTime":"0","endTime":"0","summary":"格隆汇6月29日丨劲方医药-B(02595.HK)公布，2026年6月29日，董事会正式决议行使购回股份授权，拟不定时于公开市场购回H股，最高金额不超过3.5亿港元，股份购回期限至购回股份授权期限届满。公司会在符合香港联合交易所有限公司证券上市规则的情况下进行股份购回。\r\n\r\n　　董事会认为，目前股份的交易价格低估了公司的内在价值及发展前景，而进行股份购回将提升股东价值。股份购回表明董事会对公司长期发展的信心，且仅会在董事会经持续评估公司业务前景、财务状况、股价表现及市场环境，认为适当且符合公司及股东整体利益的情况下进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260629/32292864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","02595","09939","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340711","title":"劲方医药-B(02595.HK)拟不超过3.5亿港元回购H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340711?lang=zh_cn&edition=full","pubTime":"2026-06-29 12:12","pubTimestamp":1782706342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","09939","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340938","title":"港股异动 | 劲方医药-B(02595.HK)午前涨超15% 宣布GFH375/VS-7375海外II期PDAC研究完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340938","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340938?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:40","pubTimestamp":1782704406,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02595","BK1515","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646825025","title":"交银国际：维持劲方医药(02595)“买入”评级 目标价58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646825025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646825025?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:24","pubTimestamp":1782357886,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将劲方医药(02595)的投资评级及目标价，分别维持“买入”及51港元。该行称，KRAS G12D 抑制剂海外临床及合作进展理想。交银国际认为,优异的海外初步数据对 VS7375 的同类最佳潜性提供进一步佐证。2H26 Verastem 将揭露 TARGET-D 101 研究的更多疗效数据.建议重点关注。海外其他重点催化剂包括:1)完成 TARGET-D 101 胰脏癌和 NSCLC 单药队列和 CRC 联合队列的入组(6月底);2)与 FDA 就一线 III 期研究设计进行讨论(2026年末)并启动入组(2027年上半年)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","EWH","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646825020","title":"交银国际：维持劲方医药(02595.HK)“买入”评级 目标价58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646825020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646825020?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:24","pubTimestamp":1782357886,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","02595","BK1574","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642354252","title":"【券商聚焦】中信建投证券首予劲方医药-B(02595)“买入”评级 指公司RAS靶向矩阵布局持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2642354252","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642354252?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:55","pubTimestamp":1781243717,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，劲方医药-B 两项研究成果入选2026年ASCO年会，其中GFH375在KRAS G12D突变胆管癌及结直肠癌后线患者中显示初步疗效，GFS202A I期数据支持GDF15/IL-6双靶向改善肿瘤恶病质的可行性。公司RAS靶向矩阵与恶病质差异化布局持续推进，首次覆盖给予“买入”评级，未给出目标价。安全性方面，GFH375在合计61例患者中≥3级TRAE发生率31.1%，TRAE导致治疗终止比例3.3%，未观察到新的安全信号。首次覆盖，给予“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983634","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117763045","title":"劲方医药-B更新2026年5月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117763045","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117763045?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:12","pubTimestamp":1780564320,"startTime":"0","endTime":"0","summary":"2026年6月4日，劲方医药科技(上海)股份有限公司发布2026年5月证券变动月报表。本次公告显示，公司本月已发行股份总数及各类股本结构未发生变化，总体保持稳定。H股已发行股数338,029,020股，面值每股人民币0.1元；未上市股份已发行股数32,337,610股，面值每股人民币0.1元。公司已发行股本总额为人民币37,036,663，与上月末保持一致。本期公告由公司联席公司秘书张巍签署并对以上数据和信息的真实性负有责任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995293","title":"劲方医药-B公布GFH375治疗癌症疗效数据 ORR达40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995293","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640995293?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:14","pubTimestamp":1780362840,"startTime":"0","endTime":"0","summary":"6月2日，劲方医药-B（02595）发布公告，宣布其GFH375单药治疗KRASG12D突变型胆管癌和结直肠癌的初步疗效数据已于6月1日的ASCO年会上进行口头报告。报告显示，20名KRASG12D突变型胆管癌患者的总体客观缓解率（ORR）为40%，疾病控制率（DCR）为95%。在600mgQD（RP2D）剂量水平的18名患者中，ORR为44.4%，DCR为94.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023756897496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1574","ORR","BK1515","BK1161","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640698161","title":"劲方医药-B(02595)：GFS202A治疗恶病质I期初步数据入选2026 ASCO年会壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2640698161","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640698161?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:22","pubTimestamp":1780273350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GDF15/IL-6 双抗 GFS202A 治疗肿瘤恶病质的 I 期初步临床数据，于当地时间5月30日登陆今年ASCO年会的壁报展示。GFS202A 为全球首款 GDF15/IL-6 双抗，I 期初步数据提示其治疗恶病质患者的安全性/耐受性优秀，并展现了其优秀疗效及药效动力学特征：在 200 mg Q3W 剂量水平即可对 GDF15 产生完全及持续抑制，并有效提升患者体重与骨骼肌含量。GFS202A 有望通过 GDF15、IL-6 双通路抑制，实现超越单抗的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02595","09939","159938","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638729105","title":"港股异动 | 劲方医药-B(02595)尾盘涨超6% 两款在研新药的临床研究成果将登陆2026 ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638729105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638729105?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:22","pubTimestamp":1779866560,"startTime":"0","endTime":"0","summary":"消息面上，劲方医药宣布，两款在研新药的临床研究成果将登陆2026 ASCO年会。此外，全球首款恶病质双抗GFS202A的临床数据也将首次在ASCO年会壁报环节展示。值得注意的是，5月25日，药物临床试验登记与信息公示平台官网显示，劲方医药登记了一项评估GFH375对比多西他赛治疗既往标准治疗失败的KRASG12D突变的局部晚期不可切除或转移性非小细胞肺癌试验参与者的随机对照、开放标签、多中心III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK4585","09939","BK1161","VXUS","BK1574","02595","BK1515","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892567","title":"劲方医药-B午前涨近5% 西南证券首次覆盖建议积极关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892567","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636892567?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:23","pubTimestamp":1779247380,"startTime":"0","endTime":"0","summary":"　　劲方医药-B盘中涨超6%，截至发稿，股价上涨4.62%，现报35.80港元，成交额1795.20万港元。　　CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。　　西南证券发布研报称，公司以产品矩阵进军胰腺癌、非小细胞肺癌、恶病质等大适应症市场，力求覆盖 1L 及各线治疗，产品进度全球领先；预计 2026-2028 年收入分别为 0.85/1.02/3.11亿元，分别同比-35%/+20%/+205%，首次覆盖，建议积极关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-20/doc-inhyphnm9433137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","02595","BK1574","BK0028","600369","BK0183","BK0188","BK0276","BK0012","BK1515","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894070","title":"港股异动 | 劲方医药-B(02595)午前涨超6% GDF15/IL-6双抗注射液获CDE临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894070","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636894070?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:16","pubTimestamp":1779246963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B午前涨超6%，截至发稿，涨5.08%，报35.96港元，成交额1681.63万港元。消息面上，CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。公开资料显示，GFS202A为全球首款靶向GDF15与IL-6的双特异性抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4017","BK4585","BK4588","159938","BK1161","02595","LU1223082519.USD","09939","CDE","LU1223082196.USD","LU1223083913.SGD","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700397","title":"西南证券：首次覆盖劲方医药(02595)建议积极关注 产品进度全球领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700397","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635700397?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:54","pubTimestamp":1778831677,"startTime":"0","endTime":"0","summary":"公司专注于肿瘤、自免和炎症性疾病的新治疗方案开发，已构建起一款包括8款候选产品的药物管线，包含1款已上市药物GFH925/氟泽雷塞以及5款临床阶段药物，具备全球第一梯队的RAS疗法矩阵以及差异化的非肿瘤领域多元临床管线。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260515/20260515155514_32942.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260515/20260515155514_32942.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600369","BK0183","BK1574","159938","BK1515","BK0276","02595","BK0028","BK0188","BK1161","09939","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183692720","title":"劲方医药-B更新4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183692720","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183692720?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:37","pubTimestamp":1778143041,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年5月7日披露了截至2026年4月30日的证券变动月报表。报告显示，公司本月已发行股本数与上月相比无变化，股本维持稳定。公告披露，公司注册资本由两部分组成：H股338,029,020股，面值人民币0.1元，合计人民币33,802,902元；未上市普通股32,337,610股，面值人民币0.1元，合计人民币3,233,761元。两者合计股数为370,366,630股，注册股本总额人民币37,036,663元，与上月底持平。公司确认，其公众持股比例符合香港联合交易所有限公司的相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604150","title":"格隆汇个股放量排行榜 | 5月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632604150?lang=zh_cn&edition=full","pubTime":"2026-05-03 17:30","pubTimestamp":1777800604,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03173056983654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00568","02583","02656","01643","09927","01429","02637","06110","02516","00189","00501","01211","02655","00558","01765","00259","09903","00178","00148","00800","02408","00019","00815","02595","01458","01347","00981","02676","02579","00709","00880","02687","01833","02276","09999","02443","00780","00220","00719","00363","00168","06938","00133","02489","09990","00909","00659","06979","00650","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632158966","title":"格隆汇个股放量排行榜 | 5月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632158966","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632158966?lang=zh_cn&edition=full","pubTime":"2026-05-01 17:30","pubTimestamp":1777627804,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/01173056970876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00568","09999","00558","06821","00133","00168","06110","00178","00880","00719","02516","02276","00981","00800","02583","01347","02489","00909","00709","09990","06979","02676","01643","09927","02687","00659","02595","01765","02408","00148","00650","01833","00220","09903","02655","00780","01211","01429","02579","02637","00189","00501","00259","02443","00815","00019","06938","01458","00363","02656"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630343326","title":"劲方医药-B(02595)：Rev Med发出函件所涉主体、产品、争议事项均与公司无关","url":"https://stock-news.laohu8.com/highlight/detail?id=2630343326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630343326?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:36","pubTimestamp":1777351016,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，公司近期注意到若干报导，涉及 Revolution Medicines Inc.(“RevMed”)向第三方公司发出有关RAS抑制剂专利及商业秘密争议的函件。公司特此澄清并强调：Rev Med发出函件所涉主体、产品、争议事项均与公司无关，劲方Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权，不存在类似侵权或商业秘密争议风险。劲方针对Pan RAS抑制剂项目已构建全面的全球专利布局，涵盖GFH276化合物结构的专利已于2025年3月6日正式公开，专利保护期预计可至2044年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","02595","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185566851","title":"劲方医药宣布GFH276基于自主知识产权平台开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185566851","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185566851?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:31","pubTimestamp":1777350672,"startTime":"0","endTime":"0","summary":"劲方医药（上海）有限公司近日披露，其创新药物GFH276完全基于公司独立自主的知识产权体系研发完成。该候选药物从早期发现到临床前研究阶段，均依托企业自主研发的技术平台推进，体现了公司在原创药物开发领域的核心竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":0.1043},{"period":"1month","weight":-0.1372},{"period":"3month","weight":-0.2039},{"period":"6month","weight":0.238},{"period":"1year","weight":0.4438},{"period":"ytd","weight":0.238}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}